Long survival after neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery in a patient with hepatoid adenocarcinoma of the lung: A case report

• Published in: Human vaccines & immunotherapeutics Vol. 20; no. 1; p. 2342133
• Main Authors: Huang, Xuhua, Zhu, Linhai, Pan, Weifeng, Hu, Jian
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 31.12.2024; Taylor & Francis Group
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - therapy; Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - pathology; Adenocarcinoma of Lung - therapy; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; camrelizumab; Case Report; Chemotherapy, Adjuvant - methods; Disease-Free Survival; Hepatoid adenocarcinoma of the lung; Humans; immunotherapeutics; Immunotherapy - Cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - therapy; Male; Middle Aged; Neoadjuvant Therapy - methods; surgery; survival; Treatment Outcome; Hepatoid adenocarcinoma of the lung; immunotherapeutics; survival; camrelizumab; surgery
• ISSN: 2164-5515; 2164-554X
• DOI: 10.1080/21645515.2024.2342133

Hepatoid adenocarcinoma of the lung (HAL) is a rare and aggressive subtype of lung cancer. The prognosis for patients with HAL is generally poor and currently, there are only limited treatment options. Here, we present a case of a 47-year-old male diagnosed with locally advanced-stage HAL who achieved a remarkably long disease-free survival after receiving neoadjuvant and adjuvant camrelizumab plus chemotherapy and surgery. This case highlights the potential of immunochemotherapy plus surgery in improving outcomes for patients with HAL.